Navigation Links
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
Date:10/22/2013

NCT01622790
  • ARIA (Study ING117172). A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naive Women. National Institutes of Health Study Identifier NCT01910402.
    More information available at: http://clinicaltrials.gov/show/NCT01910402
  • Prescribing information for TIVICAY is available online at:
    https://www.viivhealthcare.com/media/58599/us_tivicay.pdfPrescribing information for EPZICOM is available online at:
    https://www.viivhealthcare.com/media/70430/us_epzicom.pdf  

     ViiV UK/U.S. Media enquiries:

    Rebecca Hunt

    +44 (0) 20 8380 6275Marc Meachem

    +1 919 483 8756GSK Global Media enquiries:

    David Daley

    +44 (0) 20 8047 5502Melinda Stubbee

    +1 919 483 2510GSK Analyst/Investor enquiries:

    Lucy Budd

    +44 (0) 20 8047 2248Tom Curry

    + 1 215 751 5419Gary Davies

    + 44 (0) 20 8047 5503James Dodwell

    + 44 (0) 20 8047 2406Jeff McLaughlin

    + 1 215 751 7002Ziba Shamsi

    + 44 (0) 20 8047 3289GlaxoSmithKline cautionary statement regarding forward-looking statements: GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under Item 3.D "Risk factors" in the company's Annual Report on Form 20-F for 2012.


    '/>"/>
    SOURCE ViiV Healthcare
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Global Healthcare Leader Deploys QUOSAs Literature Management Tools
    2. Sysmex America Leads Educational Offerings Focused on Healthcare Reforms Impact on the Clinical Laboratory
    3. Hyland Software Partners with the Global Center for Healthcare Innovation in Cleveland
    4. Allied Healthcare Products Reports Loss On Sales Decline
    5. 50 Years Old and Still Bounding Over the Counter: Klines Healthcare Practice Continues to Deliver Unmatched OTC Market Intelligence
    6. Experian Healthcare launches tool to enable providers to identify and help enroll eligible individuals for health insurance exchange (HIX) subsidized programs
    7. BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
    8. Orange County Hospital System, Integrated Healthcare Holdings, Joins ApolloMed ACO
    9. ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
    10. Hubble Telemedical Welcomes Healthcare Visionary Jonathan Lord, M.D. to Its Board of Directors
    11. Piramal
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
    (Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
    (Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
    Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
    ... 2, 2011 Men who take non-steroidal anti-inflammatory drugs three ... times more likely to have erectile dysfunction compared to men ... Kaiser Permanente study published online in The Journal of ... trend toward this same finding, this observational study used electronic ...
    ... SILVER SPRING, Md., March 2, 2011 The U.S. ... that manufacture, distribute, or market certain unapproved prescription oral ... be legally marketed in the United States. ... cough, cold, and allergy drug products have not been ...
    Cached Medicine Technology:Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3FDA Prompts Removal of Unapproved Drugs From Market 2FDA Prompts Removal of Unapproved Drugs From Market 3
    (Date:2/28/2015)... The World Scout League Commission (WSLC), an ... EMTs and firefighters, recently announced its decision to host ... raise charitable donations for age-related research. The five-kilometer race, ... held on March 29, 2015; registration will start at ... p.m. , To participate in the race, runners ...
    (Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), a common ... earlier than Whites/Caucasians or African Americans, according to a ... previous research indicated that Hispanics tend to have more ... published online in the journal Alcoholism: Clinical and Experimental ... pinpoint racial and ethnic disparities in the ages at ...
    (Date:2/27/2015)... February 27, 2015 A new study ... correlation between men who cycle on a regular basis and ... the study suggests that the more hours per week a ... prostate cancer, leading to an increased importance on prostate cancer ... physicians to look more closely at patents’ risk factors for ...
    (Date:2/27/2015)... Today, February 27th, is "Shine A Light On ... LXR Organics and Living Fuel, Inc. , ... awareness and promote prevention, rescue and restoration for people held ... IT Coalition, slavery is the 2nd largest global organized crime, ... countries around the world. Slavery includes bonded labor, forced labor, ...
    (Date:2/27/2015)... CA (PRWEB) February 27, 2015 Altec ... LLP (BPW) has been chosen as their doc-link for ... GP, CRM and other complimentary solutions for their customers ... working with credit unions. Altec and BPW have worked ... doc-link’s integration to Dynamics GP. , “We are so ...
    Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
    ... Metric Ton of CO2 ... in Emissions Possible, PITTSBURGH, May 28 As ... move the United States toward a,mandatory price for carbon ... provides the clearest picture yet of,the possible short-term effects ...
    ... PainSmart Infusion Pumps Undergo,Immediate Testing to ... MEETING, Pa., May 28 ECRI ... organization that,researches the best approaches to ... medical device alert on its Web ...
    ... Following are remarks by,Attorney General Michael B. Mukasey on ... Thank you, and good afternoon. I,m pleased to be ... the Justice Department is doing to,fight health care fraud. ... the Criminal Division, and everyone here for your hard,work., ...
    ... , , WEDNESDAY, May 28 (HealthDay News) -- Two new ... , Almost 15 percent of Americans are constipated at any ... of two reports in the May 29 issue of the ... on the efficacy of the experimental drug prucalopride on 620 ...
    ... provides targeted searches to Advanced Practice Clinicians, ... in the,delivery of clinical information to Advance Practice ... clinical,nurse specialists), has announced the launch of a ... )., As part of APCToday.com,s continued commitment ...
    ... ANGELES, May 28 Dr. Jeffrey Cummings, Medical,Director ... at UCLA,received the prestigious Ronald and Nancy Reagan ... team devote themselves to, discovering new,treatments and methods ... disorders., In his speech of acceptance at ...
    Cached Medicine News:Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 2Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 3Health News:ECRI Institute Issues Priority Alert About Two Infusion Pumps 2Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 2Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 3Health News:Two Drugs Show Promise Against Severe Constipation 2Health News:Two Drugs Show Promise Against Severe Constipation 3Health News:APCTODAY.com and Convera(R) Launch Vertical Search Site for Advanced Practice Clinicians 2
    Four way compression with simple contact closure...
    Facial Chin and Neck Support...
    Abdominal Compression for Men and Women...
    Male high waisted compression girdle with CDIs Wonderfabric™...
    Medicine Products: